Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease

CONCLUSION: This emulated target trial showed that SGLT2i use was associated with a lower risk for dialysis, cardiovascular events, DKA, and AKI than no SGLT2i use in patients with T2D and stage 5 CKD.PRIMARY FUNDING SOURCE: National Health Research Institutes, Taiwan.PMID:38684099 | DOI:10.7326/M23-1874

Source: Annals of Internal Medicine - April 29, 2024 Category: Internal Medicine Authors: Fu-Shun Yen Chii-Min Hwu Jia-Sin Liu Yi-Ling Wu Keong Chong Chih-Cheng Hsu Source Type: research